MYGNMyriad Genetics, Inc.
What is the market doing?
No clear lean: rangebound and heavily shorted.
Choppy, but holding above its 200-day average. Price is +27% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, about a week of normal trading to cover.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How MYGN is trading
Myriad Genetics, Inc. is −26% over the past year while the S&P 500 is +16%: 42 points behind the market. Through the fall, its own insiders bought $28K more stock than they sold.
1-year return · S&P 500 +16%
- vs 200-day average
- +27%
vs 200-day average · a clear uptrend
- RSI (14)
- 69
RSI (14) · neutral
- Below its 52-week high
- 29%
Below its 52-week high
Details›
- Last close2026-10-23
- $5.83
- 1 monthS&P 500 −0.94%
- +40%
- 1 yearS&P 500 +16%
- −26%
- 5 yearsS&P 500 +86%
- −82%
- vs 50-day average$3.88
- +50%
- 52-week high
- $8.18
- 52-week low
- $2.87
- Annualised volatility
- 83%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-22
- $28K
| Year | Return |
|---|---|
| 2026 (year to date) | −5.3% |
| 2025 | −55% |
| 2024 | −28% |
| 2023 | +32% |
| 2022 | −47% |
| 2021 | +40% |
| 2020 | −27% |
| 2019 | −6.3% |
| 2018 | −15% |
| 2017 | +106% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +6.9% |
| Feb | 10 | 3 of 10 | −5.4% |
| Mar | 10 | 4 of 10 | −1.4% |
| Apr | 10 | 2 of 10 | −5.2% |
| May | 10 | 4 of 10 | −3.9% |
| Jun | 10 | 8 of 10 | +10% |
| Jul | 11 | 7 of 11 | +0.51% |
| Aug | 11 | 7 of 11 | +4.9% |
| Sep | 11 | 5 of 11 | +3.8% |
| Oct | 11 | 4 of 11 | +2.6% |
| Nov | 10 | 3 of 10 | −5.2% |
| Dec | 10 | 4 of 10 | −4.9% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.
Diagnostics & Research
Ranks #16 of 21 by RyuScore